These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25163357)

  • 1. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease.
    Sumida Y; Yonei Y; Tanaka S; Mori K; Kanemasa K; Imai S; Taketani H; Hara T; Seko Y; Ishiba H; Okajima A; Yamaguchi K; Moriguchi M; Mitsuyoshi H; Yasui K; Minami M; Itoh Y
    Hepatol Res; 2015 Jul; 45(7):771-81. PubMed ID: 25163357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Relationship between the Growth Hormone/Insulin-like Growth Factor System and the Histological Features of Nonalcoholic Fatty Liver Disease.
    Chishima S; Kogiso T; Matsushita N; Hashimoto E; Tokushige K
    Intern Med; 2017; 56(5):473-480. PubMed ID: 28250290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients.
    Sumida Y; Yonei Y; Kanemasa K; Hara T; Inada Y; Sakai K; Imai S; Hibino S; Yamaguchi K; Mitsuyoshi H; Yasui K; Minami M; Itoh Y; Naito Y; Yoshikawa T; Okanoue T
    Hepatol Res; 2010 Sep; 40(9):901-10. PubMed ID: 20887595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Osganian SA; Subudhi S; Masia R; Drescher HK; Bartsch LM; Chicote ML; Chung RT; Gee DW; Witkowski ER; Bredella MA; Lauer GM; Corey KE; Dichtel LE
    Growth Horm IGF Res; 2022 Aug; 65():101482. PubMed ID: 35780715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GH/IGF-1 Axis Is Associated With Intrahepatic Lipid Content and Hepatocellular Damage in Overweight/Obesity.
    Dichtel LE; Corey KE; Haines MS; Chicote ML; Kimball A; Colling C; Simon TG; Long MT; Husseini J; Bredella MA; Miller KK
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3624-e3632. PubMed ID: 35779256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver.
    Takahashi Y
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28678199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Growth Hormone and Insulin Growth Factor 1 in the Development of Non-Alcoholic Steato-Hepatitis: A Systematic Review.
    Cristin L; Montini A; Martinino A; Scarano Pereira JP; Giovinazzo F; Agnes S
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD - a pilot study.
    Hagström H; Stål P; Hultcrantz R; Brismar K; Ansurudeen I
    Scand J Gastroenterol; 2017 Dec; 52(12):1427-1434. PubMed ID: 28927302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Prevalence of Nonalcoholic Fatty Liver Disease Among Adolescents and Young Adults With Hypopituitarism due to Growth Hormone Deficiency.
    Kang SJ; Kwon A; Jung MK; Chae HW; Kim S; Koh H; Shin HJ; Kim HS
    Endocr Pract; 2021 Nov; 27(11):1149-1155. PubMed ID: 34126247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease.
    Koo BK; Um SH; Seo DS; Joo SK; Bae JM; Park JH; Chang MS; Kim JH; Lee J; Jeong WI; Kim W
    Liver Int; 2018 Apr; 38(4):695-705. PubMed ID: 28898507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease.
    Ichikawa T; Nakao K; Hamasaki K; Furukawa R; Tsuruta S; Ueda Y; Taura N; Shibata H; Fujimoto M; Toriyama K; Eguchi K
    Hepatol Int; 2007 Jun; 1(2):287-94. PubMed ID: 19669352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of factors influencing glucose tolerance in Japanese patients with non-alcoholic fatty liver disease.
    Ohmi S; Ono M; Takata H; Hirano S; Funakoshi S; Nishi Y; Yoshimura K; Amano E; Terada Y; Saibara T; Fujimoto S
    Diabetol Metab Syndr; 2017; 9():65. PubMed ID: 28878826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum homocysteine levels in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Patsiaoura K; Katsiki E; Zafeiriadou E; Deretzi G; Zavos C; Gavalas E; Katsinelos P; Mane V; Slavakis A
    Ann Hepatol; 2012; 11(1):68-76. PubMed ID: 22166563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between growth hormone deficiency and nonalcoholic fatty liver disease in patients with pituitary stalk interruption syndrome.
    Huang Q; Xu H; Wang X; Mao J; Yu B; Zhu Y; Zhang R; Sun B; Zhang J; Ji W; Ma W; Nie M; Wu X
    Clin Endocrinol (Oxf); 2022 Nov; 97(5):612-621. PubMed ID: 35384023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
    Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
    BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers.
    Mizuno M; Shima T; Oya H; Mitsumoto Y; Mizuno C; Isoda S; Kuramoto M; Taniguchi M; Noda M; Sakai K; Koyama N; Okanoue T
    Hepatol Res; 2017 Feb; 47(2):216-225. PubMed ID: 26997642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD.
    Marques V; Afonso MB; Bierig N; Duarte-Ramos F; Santos-Laso Á; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Luís R; Costa A; Machado MV; Alonso C; Arretxe E; Alustiza JM; Krawczyk M; Lammert F; Tiniakos DG; Flehmig B; Cortez-Pinto H; Banales JM; Castro RE; Normann A; Rodrigues CMP
    Front Med (Lausanne); 2021; 8():683250. PubMed ID: 34249975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.